Quart Barry D
Known title: Chief Executive OfficerCIK: 0001384243
Associated companies
this person other insiders at KNSA
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Heron Therapeutics Signs U.S. License Deal. Heron Therapeutics has entered a multi-product development and license agreement granting it exclusive rights to market products in the U.S. The company is obligated to pay milestone and royalty payments under this new arrangement. This development provides a potential pathway for future revenue, though the stock currently trades well below the average analyst target price.
Transaction History
| KNSA | ▼ Sell | Gift | 2,600 | $0 | 8/19/2026 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 2,799 | — | 5/29/2026 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 13,099 | $188K | 4/28/2026 | View on chart |
| KNSA | ▼ Sell | Open Market | 13,099 | $656K | 4/28/2026 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 6,901 | $99K | 4/6/2026 | View on chart |
| KNSA | ▼ Sell | Open Market | 6,901 | $345K | 4/6/2026 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 2,690 | $42K | 2/12/2026 | View on chart |
| KNSA | ▼ Sell | Open Market | 2,690 | $121K | 2/12/2026 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 110 | $2K | 2/10/2026 | View on chart |
| KNSA | ▼ Sell | Open Market | 110 | $5K | 2/10/2026 | View on chart |
| KNSA | ▼ Sell | Open Market | 2,602 | $117K | 2/4/2026 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 2,602 | $40K | 2/4/2026 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 12,528 | $194K | 2/3/2026 | View on chart |
| KNSA | ▼ Sell | Open Market | 12,528 | $567K | 2/3/2026 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 830 | $13K | 2/2/2026 | View on chart |
| KNSA | ▼ Sell | Open Market | 830 | $37K | 2/2/2026 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 20,129 | $209K | 12/15/2025 | View on chart |
| KNSA | ▼ Sell | Open Market | 20,129 | $836K | 12/15/2025 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 12,336 | $47K | 6/11/2025 | View on chart |
| KNSA | ▼ Sell | Open Market | 12,336 | $375K | 6/11/2025 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 8,212 | $31K | 6/10/2025 | View on chart |
| KNSA | ▼ Sell | Open Market | 8,212 | $249K | 6/10/2025 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 6,900 | $26K | 6/9/2025 | View on chart |
| KNSA | ▼ Sell | Open Market | 6,900 | $209K | 6/9/2025 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 3,173 | — | 6/5/2025 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 4,373 | — | 6/6/2024 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 5,000 | — | 6/29/2023 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 3,645 | — | 1/13/2023 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 16,122 | — | 1/13/2023 | View on chart |
| HRTX | ▼ Sell | Tax Withholding | 5,219 | $17K | 1/13/2023 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 21,959 | $35K | 11/29/2022 | View on chart |
| KNSA | ▼ Sell | Open Market | 21,959 | $355K | 11/29/2022 | View on chart |
| HRTX | ▼ Sell | Other | 1,655 | $5K | 10/31/2022 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 3,646 | — | 10/13/2022 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 16,122 | — | 10/13/2022 | View on chart |
| HRTX | ▼ Sell | Tax Withholding | 5,219 | $20K | 10/13/2022 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 3,646 | — | 7/13/2022 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 16,122 | — | 7/13/2022 | View on chart |
| HRTX | ▼ Sell | Tax Withholding | 5,219 | $16K | 7/13/2022 | View on chart |
| HRTX | ▼ Sell | Other | 1,504 | $6K | 4/29/2022 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 3,646 | — | 4/13/2022 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 16,122 | — | 4/13/2022 | View on chart |
| HRTX | ▼ Sell | Tax Withholding | 5,219 | $32K | 4/13/2022 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 3,646 | — | 1/13/2022 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 16,122 | — | 1/13/2022 | View on chart |
| HRTX | ▼ Sell | Tax Withholding | 5,219 | $43K | 1/13/2022 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 3,646 | — | 10/13/2021 | View on chart |
| HRTX | ▼ Sell | Tax Withholding | 963 | $10K | 10/13/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Kiniksa Reports Strong Growth and Accelerating Earnings
Kiniksa Pharmaceuticals has reported earnings that are accelerating, supporting its growth narrative. Analysts note that the company’s performance shows little room for disappointment, reinforcing confidence in its business model. The company’s recent data underscores its position as a solid growth player in the pharmaceutical sector.
Kiniksa Reports Strong Growth and Accelerating Earnings. Kiniksa Pharmaceuticals has reported earnings that are accelerating, supporting its growth narrative. Analysts note that the company’s performance shows little room for disappointment, reinforcing confidence in its business model. The company’s recent data underscores its position as a solid growth player in the pharmaceutical sector.